Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotechnology company specializing in molecular glue degrader (MGD)-based medicines, has announced its upcoming participation at the TD Cowen 45th Annual Health Care Conference. The company's CEO, Markus Warmuth, M.D., will deliver a presentation on Monday, March 3, 2025, at 2:30 p.m. EST.
The presentation will be accessible through a webcast available in the 'Events & Presentations' section of Monte Rosa's investor relations website at ir.monterosatx.com. An archived version of the presentation will remain available for 30 days after the event.
Monte Rosa Therapeutics (Nasdaq: GLUE), una compagnia biotecnologica in fase clinica specializzata in medicinali basati su degradatori di molecole adesive (MGD), ha annunciato la sua prossima partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. Il CEO dell'azienda, Markus Warmuth, M.D., terrà una presentazione lunedì 3 marzo 2025, alle 14:30 EST.
La presentazione sarà accessibile tramite un webcast disponibile nella sezione 'Eventi & Presentazioni' del sito web delle relazioni con gli investitori di Monte Rosa all'indirizzo ir.monterosatx.com. Una versione archiviata della presentazione rimarrà disponibile per 30 giorni dopo l'evento.
Monte Rosa Therapeutics (Nasdaq: GLUE), una empresa de biotecnología en etapa clínica especializada en medicamentos basados en degradadores de pegamento molecular (MGD), ha anunciado su próxima participación en la 45ª Conferencia Anual de Salud de TD Cowen. El CEO de la compañía, Markus Warmuth, M.D., realizará una presentación el lunes 3 de marzo de 2025, a las 2:30 p.m. EST.
La presentación estará accesible a través de un webcast disponible en la sección 'Eventos y Presentaciones' del sitio web de relaciones con inversionistas de Monte Rosa en ir.monterosatx.com. Una versión archivada de la presentación estará disponible durante 30 días después del evento.
몬테 로사 테라퓨틱스 (Nasdaq: GLUE)는 분자 접착제 분해제 (MGD) 기반 의약품을 전문으로 하는 임상 단계의 생명공학 회사로, TD Cowen 제45회 연례 헬스케어 콘퍼런스에 참여할 예정이라고 발표했습니다. 회사의 CEO인 Markus Warmuth, M.D.는 2025년 3월 3일 월요일, 오후 2시 30분 EST에 발표를 진행할 것입니다.
발표는 몬테 로사의 투자자 관계 웹사이트의 '이벤트 및 발표' 섹션에서 제공되는 웹캐스트를 통해 접근할 수 있습니다. 발표의 아카이브 버전은 이벤트 후 30일 동안 이용 가능할 것입니다.
Monte Rosa Therapeutics (Nasdaq: GLUE), une société de biotechnologie en phase clinique spécialisée dans les médicaments basés sur des dégradateurs de colle moléculaire (MGD), a annoncé sa prochaine participation à la 45e Conférence Annuelle sur la Santé de TD Cowen. Le PDG de la société, Markus Warmuth, M.D., fera une présentation le lundi 3 mars 2025, à 14h30 EST.
La présentation sera accessible via un webcast disponible dans la section 'Événements & Présentations' du site web des relations investisseurs de Monte Rosa à l'adresse ir.monterosatx.com. Une version archivée de la présentation sera disponible pendant 30 jours après l'événement.
Monte Rosa Therapeutics (Nasdaq: GLUE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf medikamentöse Behandlungen mit molekularen Kleberabbauern (MGD) spezialisiert hat, hat seine bevorstehende Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen bekannt gegeben. Der CEO des Unternehmens, Markus Warmuth, M.D., wird am Montag, den 3. März 2025, um 14:30 Uhr EST eine Präsentation halten.
Die Präsentation wird über einen Webcast zugänglich sein, der im Abschnitt 'Veranstaltungen & Präsentationen' der Investor-Relations-Website von Monte Rosa unter ir.monterosatx.com verfügbar ist. Eine archivierte Version der Präsentation wird 30 Tage nach der Veranstaltung verfügbar bleiben.
- None.
- None.
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 2:30 p.m. EST.
A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.
Investors
Andrew Funderburk
ir@monterosatx.com
Media
Cory Tromblee, Scient PR
media@monterosatx.com
FAQ
When is Monte Rosa Therapeutics (GLUE) presenting at the TD Cowen Healthcare Conference 2025?
How long will Monte Rosa Therapeutics' (GLUE) TD Cowen conference presentation be available online?
Where can investors access Monte Rosa Therapeutics' (GLUE) TD Cowen conference presentation?
Who will represent Monte Rosa Therapeutics (GLUE) at the TD Cowen Healthcare Conference 2025?
